Children who received a greater degree of maternal warmth at 3 years had greater perceived social safety at adolescence, which in turn resulted in improved physical and mental well-being, according to a recent study in JAMA Psychiatry.
Advertisement
A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline.
The FDA has granted Orphan Drug Designation to veverimer for anti–glomerular basement membrane (anti-GBM) disease.
Fibrate use is associated with higher incidence of CKD but lower risk for ESKD and mortality, a study found.
Vivien Sheehan, MD, explained how a novel assay can guide personalized therapeutic approaches for sickle cell disease.
TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.
Epilepsy and seizure drug use were significantly more common in patients with FTD vs those with Alzheimer’s.
SLL-1-43, a selenium compound, reduced colitis symptoms in mice by targeting NOX2 and easing inflammation, oxidative stress.
Dr. Patt discusses how AI is transforming oncology care, and how to implement it responsibly and effectively.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Vivien Sheehan, MD, explained how a novel assay can guide personalized therapeutic approaches for sickle cell disease.
Rilzabrutinib significantly decreased spleen weight and reduced inflammation in mice with homozygous sickle cell genotype.
MIRCA is a device designed to assess the flexibility of red blood cells of patients with sickle cell disease.
The study will assess the overall response to olutasidenib plus azacitidine in higher-risk MDS, CMML, and advanced MPNs.
In a study, patients with T2DM and MGUS who used GLP-1 agonists were observed over 10 years to have reduced MM rates.
Arm D of the SEQUOIA trial evaluated the combo in patients with either del(17p) or TP53 mutation, both mutations, or neither.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.